Skip to main content

Table 1 Characteristics of systemic sclerosis patients included in the study

From: Identification of NF-κB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis

  French cohort (n = 1,022) Italian cohort (n = 594) Combined cohort (n = 1,616)
Age in years, mean ± SD 57.4 ± 13.9 48.8 ± 13.4 53.1 ± 13.6
Male gender, number 152 55 207
Disease duration in years, mean ± SD 13.1 ± 7.1 12.4 ± 8.7 12.75 ± 7.9
lcSSc, percentage 60 74.7 64.4
dcSSc, percentage 29.5 25.2 28
Lung fibrosis seen on CT, percentage 36.1 34.6 35.3
FVC <75%, percentage 14 16.1 14.6
Digital ulcers (ever occurred), percentage 33 44 36.6
ACA+, percentage 32.3 44.6 36.6
Anti-topo I+, percentage 23 32.6 26.3
Associated AID, percentage 15 14.6 15
  1. ACA, anti-centromere antibody; anti-topo I, anti-topoisomerase antibody; associated AID, at least one associated autoimmune disease; CT, computed tomography; dcSSc, diffuse cutaneous systemic sclerosis; FVC, forced vital capacity; lcSSc, limited cutaneous systemic sclerosis; SD, standard deviation.